Observational studyMedicina (Kaunas, Lithuania)2024

Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease.

Špela Pintar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.